Warrants of series TO2 were subscribed to approximately 1.65 percent and Pharmacolog i Uppsala AB receives approximately SEK 6.6 thousand
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE USA, AUSTRALIA, BELARUS, HONGKONG, JAPAN, CANADA, NEW ZEELAND, RUSSIA, SCHWEIZ, SINGAPORE, SOUTH AFRICA, SOUTH KOREAOR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. PLEASE REFER TO IMPORTANT INFORMATION AT THE END OF THE PRESS RELEASE.
Pharmacolog i Uppsala AB (publ) (“Pharmacolog” or “the Company”) today announces the outcome of the exercise of warrants of series TO2, which were issued in connection with the Company’s rights issue of units on Nasdaq First North Growth Market in September 2022. In total, 33,757 warrants of series TO2 were exercised, corresponding to approximately 1.65 percent of the total number of outstanding warrants of series TO2, for subscription of 36,452 shares. Pharmacolog will receive approximately SEK 6.6 thousand before issuing costs through the exercise of the warrants of series TO2.
The exercise period for exercise of the warrants of series TO2 took place during the period from and including October 4, 2023, up to and including October 18, 2023. The subscription price per share for exercising the warrants of series TO2 was set to SEK 0.18.
In total, 33,757 warrants of series TO2 were exercised for subscription 36,452 shares, meaning that approximately 1.65 percent of all outstanding warrants of series TO2 were exercised for subscription of shares.
Exercised warrants have been replaced with interim shares (IA), pending registration with the Swedish Companies Registration Office. The interim shares are expected to be converted to shares within approximately three (3) weeks.
Number of shares, share capital and dilution
Through the exercise of the warrants of series TO2, the number of shares in Pharmacolog increases by 36,452 shares, from 66,213,890 shares to a total of 66,250,342 shares. The share capital will increase by 6,452.00 SEK, from SEK 11,719,858.53 to SEK 11,726,310.53.
For existing shareholders who did not exercise any warrants of series TO2, the dilution amounts to approximately 0.06 percent of the number of shares and votes in the Company.
Mangold Fondkommission AB is financial advisor to Pharmacolog in connection with the utilization of warrants. Eversheds Sutherland Advokatbyrå AB is legal advisor to the Company in connection with the utilization of warrants.
Pharmacolog provides solutions and products that enhance work efficiency and safety when preparing injectable medication. Our goal is to help prevent medication errors and ensure maximum medication efficacy when treating patients with powerful yet potentially harmful injectable drugs. Pharmacolog’s products help staff at pharmacies and hospital wards minimize the risk of errors in the compounding process. Furthermore, by verifying that drugs and narcotics used in surgery have not been tampered with, our solutions also make a vital contribution to preventing drug diversion.
The company's Certified Adviser is Mangold Fondkommission AB.
The publication, announcement or distribution of this press release may in certain jurisdictions be subject to legal restrictions and persons in the jurisdictions in which this press release has been published or distributed should inform themselves about and observe such legal restrictions. The recipient of this press release is responsible for using this press release and the information contained herein in accordance with the applicable rules in each jurisdiction. This press release does not constitute an offer or an invitation to acquire or subscribe for any securities in Pharmacolog in any jurisdiction, neither from Pharmacolog nor from anyone else.
This press release does not constitute an offer or invitation to acquire or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States absent registration or an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public offering of such securities in the United States. The information contained in this press release may not be announced, published, copied, reproduced or distributed, directly or indirectly, in whole or in part, in or into Australia, Canada, Hong Kong, Japan, New Zealand, South Africa, Switzerland, the United States, Belarus, Russia or any other jurisdiction where such announcement, publication or distribution of this information would be contrary to applicable law or where such action is subject to legal restrictions or would require additional registration or other measures than those required by Swedish law. Actions in violation of this instruction may constitute a violation of applicable securities laws.